具有预定药物组合的双药物骨干多前药用于协同化疗。
Dual-Drug Backboned Polyprodrug with a Predefined Drug Combination for Synergistic Chemotherapy.
机构信息
Guangzhou First People's Hospital, School of Biomedical Sciences and Engineering, Guangzhou International Campus, South China University of Technology, Guangzhou 511442, P.R. China.
National Engineering Research Center for Tissue Restoration and Reconstruction, South China University of Technology, Guangzhou 510006, P.R. China.
出版信息
Nano Lett. 2021 Mar 10;21(5):2216-2223. doi: 10.1021/acs.nanolett.0c05028. Epub 2021 Feb 26.
The codelivery of drugs at specific optimal ratios to cancer cells is vital for combination chemotherapy. However, most of the current strategies are unable to coordinate the loading and release of drug combinations to acquire precise and controllable synergistic ratios. In this work, we designed an innovative dual-drug backboned and reduction-sensitive polyprodrug PEG-P(MTO-ss-CUR) containing the anticancer drugs mitoxantrone (MTO) and curcumin (CUR) at an optimal synergistic ratio to reverse drug resistance. Due to synchronous drug activation and polymer backbone degradation, drug release at the predefined ratio with a synergistic anticancer effect was demonstrated by and experiments. Therefore, the dual-drug delivery system developed in this work provides a novel and efficient strategy for combination chemotherapy.
在癌症细胞中以特定最佳比例递药对于联合化疗至关重要。然而，大多数当前策略都无法协调药物组合的加载和释放以获得精确和可控的协同比例。在这项工作中，我们设计了一种创新的双药物骨干和还原敏感的聚前药 PEG-P（MTO-ss-CUR），其中含有最佳协同比例的抗癌药物米托蒽醌（MTO）和姜黄素（CUR），以逆转耐药性。由于同步药物激活和聚合物主链降解，通过 和 实验证明了以协同抗癌作用的预定比例进行药物释放。因此，本工作中开发的双药物递送系统为联合化疗提供了一种新颖而有效的策略。
Zotero 插件